All articles
Evidence-led research on repurposed compounds and the protocols people actually ask about — cited to primary literature and reviewed for accuracy.
Ivermectin + Mebendazole Study: From Expression of Concern to Retraction (2026)
Anticancer Research flagged the widely-shared Hulscher et al. study (84.4% clinical benefit) with a formal Expression of Concern: no control group, self-reported outcomes. The paper has not been retracted as of August 2026.
Fenbendazole
Fenbendazole for Brain Cancer & Glioblastoma: BBB Penetration and Evidence
Can fenbendazole cross the blood-brain barrier? Evidence for glioblastoma treatment, BBB penetration studies, and clinical considerations for brain tumor protocols.
Mebendazole Shows Antiproliferative Activity in Childhood Low-Grade Brain Tumor Models (2026)
A June 2026 preclinical study from Rome found mebendazole significantly inhibited cell growth and migration in two pediatric low-grade glioma cell lines, supporting its potential as a repositioned therapeutic drug.
Fenbendazole
Fenbendazole for Skin Cancer & Melanoma: Evidence, Cases and Risks (2026)
Can fenbendazole fight melanoma? We review the preclinical evidence, mechanisms of action, and what the current cancer research actually shows.
182 Cancer Patients Reported Using Fenbendazole at MD Anderson: ASCO 2026 Review
A 2026 ASCO abstract documents 182 self-reported fenbendazole users at MD Anderson out of 297,223 patients — with 138 different dosing schedules. A prevalence snapshot with major implications for research design.
protocols
ISOM Protocol (Dr. William Makis): Drugs, Dosing, Publications & Criticisms (2026)
The Integrative Supportive Oncology Medicine protocol combining multiple repurposed drugs. Complete breakdown of components, synergistic effects, and clinical implementation strategies.
Fenbendazole
Joe Tippens Protocol: Complete Guide to Fenbendazole Cancer Protocol
Complete Joe Tippens cancer protocol guide: fenbendazole dosing, supplements, latest research, safety data, and step-by-step implementation. Updated 2026.
Ivermectin Suppresses Gastric Cancer in Patient-Derived Organoids (2026 Study)
A June 2026 South Korean study found ivermectin suppressed gastric cancer growth in patient-derived 3D organoids, achieving 82.48% cell death when combined with cisplatin — a more realistic tumor model than standard cell lines.
Fenbendazole
Fenbendazole for Ovarian Cancer: Nanoparticle Delivery & Platinum-Resistant Disease
Breakthrough nanoparticle delivery systems for fenbendazole in ovarian cancer. Targeting platinum-resistant disease and overcoming chemotherapy failure with novel formulations.
Curcumin Selectively Disrupts Cancer Cell Energy: New 2026 Study (Wrocław University)
A July 2026 study from Wrocław found curcumin cut ATP in fibrosarcoma cells by up to 92% and drove 75% into permanent senescence — outperforming four other natural compounds with the best safety profile.
protocols
Care Oncology Protocol (COC): Metabolic Therapy with Metformin, Atorvastatin, Doxycycline & Mebendazole
The COC Protocol combines four repurposed drugs for metabolic cancer therapy. Clinical evidence for metformin, atorvastatin, doxycycline, and mebendazole in multi-modal treatment.
Fenbendazole
Fenbendazole for Prostate Cancer: Evidence, Mechanisms & Patient Experiences
Fenbendazole mechanisms specific to prostate cancer treatment. Patient experiences, anti-androgen synergies, and evidence from preclinical and anecdotal sources.
Nothing here yet.